Instil Bio, Inc.

TIL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item Jun 2024 Mar 2024 Sep 2023 Dec 2021 Sep 2021 Jun 2021 Mar 2021 Dec 2020
Revenue $0 $0 $0 $0 $0 $0 $0 $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $2.9M $7.3M $8.5M $42.6M $29.1M $21.2M $14.4M $10.2M
SG&A Expense $10.7M $12.4M $11.9M $11.2M $14.0M $14.2M $9.0M $7.2M
Operating Income $-14.1M $-24.0M $-66.7M $-53.8M $-43.0M $-35.4M $-23.4M $-17.5M
Operating Margin
Interest Expense $2.0M $2.0M $0 $0
Pretax Income $-67.4M $-54.3M $-43.7M $-35.5M $-23.3M $-17.0M
Income Tax Expense $0 $1.1M $-658.0K $-159.0K $-204.0K $151.0K
Net Income $-14.9M $-24.3M $-67.4M $-55.4M $-43.0M $-35.3M $-23.1M $-17.2M
Net Margin
EPS (Basic) $-2.29 $-3.74 $-10.37 $-0.22 $-0.05 $-0.04 $-0.09 $-0.15
EPS (Diluted) $-2.29 $-3.74 $-10.37 $-0.22 $-0.05 $-0.04 $-0.09 $-0.15
Shares Outstanding (Basic) 6.5M 6.5M 6.5M 106.0M 901.6M 901.2M 244.8M 112.0M
Shares Outstanding (Diluted) 6.5M 6.5M 6.5M 106.0M 901.6M 901.2M 244.8M 112.0M
Dividends Per Share
← Newer Page 2 of 3 Older →